For rare and debilitating diseases, patient participation in clinical trials represents a significant bottleneck, despite patient eagerness to expedite research efforts. Sanguine Biosciences accelerates your therapy programs by connecting you to patients with confirmed disease:
Prospective biospecimen collection delivers faster and more reliable samples for translational research and clinical trials by providing:
Recruiting participants who meet I/E criteria
Obtaining medical records and outcome assessments
Collecting samples in-home
Recruiting participants who meet I/E criteria
Obtaining medical records and outcome assessments
Collecting samples in-home
Read how Sanguine partnered on a 4.5 year, hybrid Phase I trial design for a novel Duchenne Muscular Dystrophy (DMD) therapeutic in this case study.